ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Free cash flow 2016–2025
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$156.9MFY2025 · since FY2016: -$68.3M → $156.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $156.9M | +126.0% |
| FY2024 | -$604.3M | -82.8% |
| FY2023 | -$330.6M | -75.0% |
| FY2022 | -$188.9M | -227.9% |
| FY2021 | $147.7M | +237.1% |
| FY2020 | -$107.8M | -166.9% |
| FY2019 | $161.0M | +431.0% |
| FY2018 | -$48.6M | -52.7% |
| FY2017 | -$31.9M | +53.3% |
| FY2016 | -$68.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ARWR financial trends
ARWR RevenueARWR Net incomeARWR Net marginARWR Gross profitARWR Gross marginARWR Operating incomeARWR Operating marginARWR Operating cash flowARWR Capital expendituresARWR Return on equityARWR Stock buybacksARWR Dividends paidARWR Total assetsARWR Total liabilitiesARWR Shareholders’ equityARWR overview →